Phase 3 Alogliptin Pediatric Study
Research Question:
Does the drug alogliptin help children age 10-17 with type 2 diabetes?
Basic Study Information
Purpose:
This study will evaluate the efficacy and safety of alogliptin 25 mg once daily (QD)
compared
to placebo when administered as monotherapy, or when added onto a background of metformin
alone, insulin alone, or a combination of metformin and insulin in pediatric participants
10
to 17 years of age with type 2 diabetes mellitus (T2DM).
Location: University of Rochester
Study Contact Information
Study Coordinator: Takeda Study Registration Call Center
Email: medicalinformation@tpna.com
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search